An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
Nocturia
About this trial
This is an interventional treatment trial for Nocturia
Eligibility Criteria
Inclusion Criteria:
- Written informed consent prior to the performance of any study-related activity.
- Was randomized into Part II of Protocol FE992026 CS29 (NCT00477490), entitled "A Randomized, Double Blind,Placebo Controlled, Parallel Group, Multi-Center Study with a Double Blind Extension Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults" and have completed at least Visit 3E in Part II (Day 15).
Exclusion Criteria:
- Patients using loop diuretics (furosemide, torsemide, ethacrynic acid).
Sites / Locations
- Radiant Research
- Arkansas Primary Care Clinic, PA
- Advanced Urology Medical Center
- Impact Clinical Trials
- California Professional Research
- San Diego Uro-Reseach
- Radiant Research
- West Coast Clinical Research
- Western Clinical Research
- Urology Associates PC
- Downtown Women's Health Care
- Genitourinary Surgical Consultants
- Connecticut Clinical Research Center, LLC
- South Florida Medical Research
- Women's Health Research Group, LLC
- Radiant Research - St. Petersburg
- Sunrise Medical Research
- Radiant Research
- Tampa Bay Urology
- Radiant Research
- Southeastern Medical Research Institute
- Investigational site
- Radiant Research, Inc
- Accelovance
- Radiant Research, Kansas City
- Benchmark Research
- Regional Urology, LLC
- FutureCare Studies, Inc.
- Radiant Research, Minneapolis
- Radiant Research, Inc.
- Women's Clinic of Lincoln, P.C.
- Sheldon J Freedman Ltd
- Central Jersey Medical Research Center
- Lawrenceville Urology, P.A. DBA
- Urology Group of New Mexico, PC
- Investigational site - Adult & Pediatric Urology
- AccuMed Research Associates
- University Urology Associates
- Upstate Urology
- Hudson Valley Urology, PC
- PharmQuest
- New Hanover Medical Research
- Piedmont Medical Research Associates
- Radiant Research Inc.
- Radiant Research - Akron
- Urologic Consultants of SE PA
- Philadelphia Clinical Research, LLC
- Advanced Clinical Concepts
- Radiant Research, Greer
- Palmetto Medical Research
- Carolina Urologic Research Center
- Holston Medical Group
- Advanced Research Associates
- Investigational site - NationsMed Clinical Research
- Accelovance
- Regional Medical Center and Diagnostic
- Innovative Clinical Trials
- Radiant Research San Antonio
- IMED Research, P.A.
- NationsMed
- Virginia Urology
- Urology of Virginia PC
- Women's Clinical Research Center
- Seattle Urology Research Center
- Southern Interior Medical Research Inc.
- Can-Med Clinical Research Inc.
- Investigational site - Clinical Research
- Investigational site - Professional Corporation
- The Male/Female Health and Research
- Brantford Urology Research
- Guelph Urology Associates
- Investigational site
- The Fe/Male Health Centres
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Desmopressin Melt 10 μg
Desmopressin Melt 25 μg
Desmopressin Melt 50 μg
Desmopressin Melt 100 μg
Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.